Mark T A Donoghue
Overview
Explore the profile of Mark T A Donoghue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
4837
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zucker M, Perry M, Gould S, Elkrief A, Safonov A, Thummalapalli R, et al.
Cell
. 2024 Dec;
188(3):851-867.e17.
PMID: 39701102
The canonical model of tumor suppressor gene (TSG)-mediated oncogenesis posits that loss of both alleles is necessary for inactivation. Here, through allele-specific analysis of sequencing data from 48,179 cancer patients,...
2.
Gormally M, Chen M, Noronha A, Panageas K, Reynolds M, Kohlasch K, et al.
JAMA Oncol
. 2024 Nov;
11(1):74-76.
PMID: 39602136
No abstract available.
3.
Safonov A, Marra A, Bandlamudi C, OLeary B, Wubbenhorst B, Ferraro E, et al.
bioRxiv
. 2024 Sep;
PMID: 39253462
The co-occurrence of germline and somatic oncogenic alterations is frequently observed in breast cancer, but their combined biologic and clinical significance has not been evaluated. To assess the role of...
4.
Rekhtman N, Tischfield S, Febres-Aldana C, Lee J, Chang J, Herzberg B, et al.
Cancer Discov
. 2024 Aug;
15(1):83-104.
PMID: 39185963
Small cell lung carcinoma (SCLC) is a highly aggressive malignancy that is typically associated with tobacco exposure and inactivation of RB1 and TP53 genes. Here, we performed detailed clinicopathologic, genomic,...
5.
Lenis A, Ravichandran V, Brown S, Alam S, Katims A, Truong H, et al.
Clin Cancer Res
. 2024 Jul;
30(17):3894-3903.
PMID: 38949888
Purpose: Patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, and response to immune...
6.
Chen M, Yang S, Tao J, Desilets A, Diamond E, Wilhelm C, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3812-3823.
PMID: 38922339
Purpose: Even though BRAF fusions are increasingly detected in standard multigene next-generation sequencing panels, few reports have explored their structure and impact on clinical course. Experimental Design: We collected data...
7.
Lin A, Rudneva V, Richards A, Zhang Y, Woo H, Cohen M, et al.
Acta Neuropathol
. 2024 May;
147(1):85.
PMID: 38758238
Pituitary neuroendocrine tumors (PitNETs) exhibiting aggressive, treatment-refractory behavior are the rare subset that progress after surgery, conventional medical therapies, and an initial course of radiation and are characterized by unrelenting...
8.
Walmsley C, Jonsson P, Cheng M, McBride S, Kaeser C, Vargas H, et al.
NPJ Precis Oncol
. 2024 Feb;
8(1):34.
PMID: 38355834
Reversion mutations that restore wild-type function of the BRCA gene have been described as a key mechanism of resistance to Poly(ADP-ribose) polymerase (PARP) inhibitor therapy in BRCA-associated cancers. Here, we...
9.
Rosenbaum E, Seier K, Bradic M, Kelly C, Movva S, Nacev B, et al.
Cancer Res Commun
. 2023 Oct;
3(10):2118-2125.
PMID: 37787759
Significance: irAE after ICB therapy was associated with an improved OS; it also approached statistical significance for improved PFS. Patients who had an irAE were more likely to have an...
10.
Gleason C, Dickson M, Klein Dooley M, Antonescu C, Gularte-Merida R, Benitez M, et al.
Clin Cancer Res
. 2023 Sep;
30(4):703-718.
PMID: 37695642
Purpose: We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth in humans. Patients And...